Day One Biopharmaceuticals, Inc.

This study compares a new drug called DAY101 (tovorafenib) to standard chemotherapy in children and young adults (under 25) with a slow-growing brain tumor (low-grade glioma) that has a specific genetic change (RAF alteration). The goal is to see if DAY101 works better at shrinki…